<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876616</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0901</org_study_id>
    <nct_id>NCT00876616</nct_id>
  </id_info>
  <brief_title>Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis</brief_title>
  <official_title>An Multi-site, Open, Prospective Study to Assess the Efficacy and Safety of Multi-target Therapy in the Treatment of Class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhi-Hong Liu, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of multi-target therapy in the
      treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To assess the efficacy of FK506 combined with MMF vs intravenous cyclophosphamide (CTX)
           pulses in treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis (LN).

        2. To investigate the safety and tolerability of FK506 combined with MMF vs intravenous CTX
           pulses in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ LN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of FK506 combined with MMF vs intravenous CTX pulses in treatment of class Ⅲ, Ⅳ,Ⅴ, Ⅲ+Ⅴand Ⅳ+Ⅴ LN.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary endpoint is the rate of complete remission at 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the other efficacy indicators of FK506 combined with MMF vs intravenous CTX pulses in the treatment of class Ⅲ, Ⅳ,Ⅴ, Ⅲ+Ⅴand Ⅳ+Ⅴ LN.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary endpoints include total remission, time to complete remission and remission, rate of complete remission and remission in patients with different types of LN, changes between baseline and after 24 week of induction treatment in proteinuria, albumin, SCr, eGFR, complement, autoantibodies, SLE-DAI and dosage and concentration of immunosuppressants between groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the Safety of FK506 combined with MMF vs intravenous CTX pulses in treatment of class Ⅲ, Ⅳ,Ⅴ, Ⅲ+Ⅴand Ⅳ+Ⅴ LN.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety assessments include clinical manifestations, physical examination, laboratory tests laboratory tests (including hematology, serum chemistry, urinalysis), adverse events (including gastrointestinal toxicity and severe infections requiring antibiotics treatment) and concomitant medications.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Tacrolimus+Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FK506 4mg/d+MMF 1.0g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTX iv 0.75 g/m2 body surface area (BSA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus+Mycophenolate mofetil</intervention_name>
    <description>FK506 4mg/d,MMF 1.0g/d</description>
    <arm_group_label>Tacrolimus+Mycophenolate mofetil</arm_group_label>
    <other_name>FK506+MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>CTX 0.75g/m2 BSA</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent by subject or guardian

          2. 18 to 65 years of age (inclusive 18 and 65), male or female

          3. Diagnosis of SLE according to the American College of Rheumatology criteria (1997)

          4. Diagnosis of Class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+ⅤLN according to the ISN/RPS 2003 classification by
             light, immunofluorescence, and electron microscopy within 6 months before enrollment

          5. Pathologic chronic index (CI) ≤3' without thrombotic microangiopathy (TMA)

          6. SLE Disease Activity Index (DAI) &gt;10'

          7. Proteinuria ≥1.5g/d，with or without active urinary sediment

          8. Serum creatinine (Scr)≤3.0mg/dl (265.2 mol/L)

        Exclusion Criteria:

          1. Previous treatment with MMF, CTX, tacrolimus, Cyclosporin A (CsA), large doses of
             immunoglobulin and methylprednisolone (MP), plasmapheresis or renal replacement
             therapy within the past 12 weeks. Oral glucocorticoids, azathioprine, intravenous MP
             (≤80mg/d)， short-time CsA (&lt;2 weeks) or leflunomide (&lt;4 weeks) are allowed

          2. ALT or AST increase twice above the upper limit of the normal range

          3. Hyperglycemia is defined as fasting blood glucose level ≥7.0 mmol/L and/or
             postprandial blood sugar level&gt;11.1 mmol/L

          4. Known hypersensitivity or contraindication to any components of MMF, tacrolimus, CTX
             or glucocorticoids

          5. History of present illness:

               1. active HBV infection (HBsAg, HBeAg and anti-HBc positive or HBsAg, anti- HBe and
                  anti-HBc positive), HCV infection, pulmonary tuberculosis, cytomegalovirus(CMV)
                  infection (defined as CMV-IgM positive or CMV-DNA positive), fungal infection or
                  HIV infection, within 3 months before the enrollment

               2. non-healed active peptic ulcer within 3 months before the enrollment

               3. drug or drinking abuse

               4. malnutrition (BMI &lt;18.5kg/m2) or body weight &lt;50Kg

          6. Other active diseases, such as:

               1. severe cardiovascular diseases

               2. chronic obstructive pulmonary disease(COPD)or asthma requiring oral
                  glucocorticoids

               3. marrow depression not due to SLE activation: white blood cell count &lt;3000/mm3 or
                  neutrophil count &lt;1300/mm3 or platelet count &lt;50000/mm3

          7. Severe infection or need of antibiotic therapy

          8. Female patients who are pregnant/breastfeeding or those patients (both gender) who
             refused contraception

          9. Life-threatening complications such as large hydropericardium, pneumohemorrhagia,
             lupus encephalopathy and severe pulmonary hypertension or patients in need of MP pulse
             (&gt;0.5g/d ) treatment because of aggravation of SLE

         10. Known to be non-compliance or violation of the protocol base on investigator's
             judgement

         11. Patient who participate of any other investigational drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhihong Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology,Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <last_update_submitted>August 28, 2013</last_update_submitted>
  <last_update_submitted_qc>August 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, M.D.</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>lupus nephritis;multi-target therapy; MMF; FK506</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

